Analysis reveals clinical benefit of zanidatamab in patients with HER2-positive salivary gland cancer, suggesting effective treatment options.
Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: